数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Gregg H. Alton -- Director 55 未披露 未持股 2021-05-03
Margaret G. McGlynn -- Director 61 未披露 未持股 2021-05-03
Rachel K. King -- Director 61 未披露 未持股 2021-05-03
Gary C. Evans Director 64 86.40万美元 未持股 2021-05-03
Gregg H. Alton Director 55 56.45万美元 未持股 2021-05-03
Stanley C. Erck Director,President and Chief Executive Officer 72 4808.60万美元 未持股 2021-05-03
James F. Young Director and chairman 68 438.77万美元 未持股 2021-05-03
Rajiv I. Modi Director 60 未披露 未持股 2021-05-03
Michael A. McManus, Jr. Director 78 87.63万美元 未持股 2021-05-03
Margaret G. McGlynn Director 61 85.49万美元 未持股 2021-05-03
Gary C. Evans Director 63 未披露 未持股 2021-05-03
Richard H. Douglas Director 68 86.15万美元 未持股 2021-05-03
David M. Mott Director 55 72.73万美元 未持股 2021-05-03
Rachel K. King Director 61 85.65万美元 未持股 2021-05-03

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
John A. Herrmann III Executive Vice President,Chief Legal Officer and Corporate Secretary 55 2060.68万美元 未持股 2021-05-03
Stanley C. Erck Director,President and Chief Executive Officer 72 4808.60万美元 未持股 2021-05-03
John Trizzino Executive Vice President,Chief Commercial Officer,Chief Business Officer and Interim Chief Financial Officer 61 2132.80万美元 未持股 2021-05-03
Gregory Glenn President, Research and Development 67 2492.34万美元 未持股 2021-05-03

董事简历

中英对照 |  中文 |  英文
Gregg H. Alton
暂无中文简介

Gregg H. Alton,Gilead Sciences,Served in an array of leadership roles across a portfolio of responsibilities for more than 20 years from 1999 to 2019 including:Interim Chief Executive Officer.Chief Patent Officer, responsible for Gilead’s government affairs, public affairs, patient outreach and engagement initiatives, as well as efforts to facilitate access to its medicines globally.Oversight for commercial operations in Europe, Asia, Latin America and Africa, as well as government affairs, public affairs and global medical affairs.General Counsel and Chief Compliance Officer.Cooley Godward, LLP,Attorney, specializing in corporate finance transactions for healthcare and information technology companies 1993 to 1996 and 1998 to 1999.J.D., Stanford University.Bachelor of Science in Legal Studies, University of California, Berkeley.
暂无中文简介
Gregg H. Alton,Gilead Sciences,Served in an array of leadership roles across a portfolio of responsibilities for more than 20 years from 1999 to 2019 including:Interim Chief Executive Officer.Chief Patent Officer, responsible for Gilead’s government affairs, public affairs, patient outreach and engagement initiatives, as well as efforts to facilitate access to its medicines globally.Oversight for commercial operations in Europe, Asia, Latin America and Africa, as well as government affairs, public affairs and global medical affairs.General Counsel and Chief Compliance Officer.Cooley Godward, LLP,Attorney, specializing in corporate finance transactions for healthcare and information technology companies 1993 to 1996 and 1998 to 1999.J.D., Stanford University.Bachelor of Science in Legal Studies, University of California, Berkeley.
Margaret G. McGlynn
暂无中文简介

Margaret G. McGlynn,President and Chief Executive Officer, leading extensive partnership efforts to advance the development, global launch and access to a broadly effective HIV vaccine 2011 to 2015.Served in leadership roles of increasing responsibility for more than two decades (1983 to 2009) including:President, U.S. Hospital and Specialty Products Division.President of Merck Vaccines and Infectious Diseases.Amicus Therapeutics (Nasdaq: FOLD).Vertex Pharmaceuticals (Nasdaq: VRTX).Honorary Doctorate, the State University of New York at Buffalo.Master’s in Business Administration and Marketing, The State University of New York at Buffalo.Bachelor of Science in Pharmacy, The State University of New York at Buffalo.
暂无中文简介
Margaret G. McGlynn,President and Chief Executive Officer, leading extensive partnership efforts to advance the development, global launch and access to a broadly effective HIV vaccine 2011 to 2015.Served in leadership roles of increasing responsibility for more than two decades (1983 to 2009) including:President, U.S. Hospital and Specialty Products Division.President of Merck Vaccines and Infectious Diseases.Amicus Therapeutics (Nasdaq: FOLD).Vertex Pharmaceuticals (Nasdaq: VRTX).Honorary Doctorate, the State University of New York at Buffalo.Master’s in Business Administration and Marketing, The State University of New York at Buffalo.Bachelor of Science in Pharmacy, The State University of New York at Buffalo.
Rachel K. King
暂无中文简介

Rachel K. King,GlycoMimetics, Inc.,Founder and Chief Executive Officer 2003 to present.New Enterprise Associates,Executive in Residence (2001 to 2003).Novartis Corporation,Senior Vice President (1999 to 2001).Genetic Therapy, Inc.,Manager of Laboratory Operations from 1989 to 1993 and Vice President for Product Planning from 1993 to 1996 including early-stage development, initial public offering and acquisition by Novartis; Chief Executive Officer of GTI, a wholly owned subsidiary of Novartis from 1996 to 1998.Mrs. King worked previously at ALZA Corporation and Bain and Company.
暂无中文简介
Rachel K. King,GlycoMimetics, Inc.,Founder and Chief Executive Officer 2003 to present.New Enterprise Associates,Executive in Residence (2001 to 2003).Novartis Corporation,Senior Vice President (1999 to 2001).Genetic Therapy, Inc.,Manager of Laboratory Operations from 1989 to 1993 and Vice President for Product Planning from 1993 to 1996 including early-stage development, initial public offering and acquisition by Novartis; Chief Executive Officer of GTI, a wholly owned subsidiary of Novartis from 1996 to 1998.Mrs. King worked previously at ALZA Corporation and Bain and Company.
Gary C. Evans

Gary C. Evans于2022年11月加入董事会。他在公共和私营金融业务部门拥有丰富的经验,并在数十亿美元公司的初创企业中拥有创业专长。此外,Gary C. Evans也有与投资者关系和金融机构成功打交道的历史。这一系列的特点使埃文斯先生成为一个伟大的和非常需要的补充United States Antimony Corporation董事会。Gary C. Evans目前担任Evergreen Sustainable Enterprises,Inc.(EGSE)董事会主席兼首席执行官,该公司是一家上市的可持续能源转型和大麻公司,目前在OTCQB交易,市值约为5000万美元,自2016年以来一直担任该职位。EGSE通过在大麻行业的各种收购实现了多元化,主要是在中游行业。埃文斯曾于2009年至2016年领导Magnum Hunter Resources Corporation,这是一家在纽约证券交易所上市、市值数十亿美元的公共能源公司,专门从事主要在阿巴拉契亚盆地和鹰福特的非常规资源开发。这些公司资产现在是西南能源公司(纽约证券交易所代码:SWN)的一部分。埃文斯还是Eureka Hunter Holdings,LLC的创始人和首席执行官,该公司是一家中游天然气采集公司,在类似的七年期间,从西弗吉尼亚州和俄亥俄州新建的约200英里管道上的油井生产天然气,每天输送和管理的天然气量高达1 BCF。此外,埃文斯先生曾在纽约证券交易所上市公司Magnum Hunter能源公司(Magnum Hunter Resources Inc.,简称MHRI)创立并担任董事长兼首席执行官长达20年,然后于2005年6月以大约22亿美元的价格将MHRI出售给Cimarex能源。这些资产现在是Coterra Energy公司(纽约证券交易所代码:CTRA)的一部分。在整个职业生涯中,埃文斯在华尔街筹集了超过70亿美元的各种形式的资金。埃文斯先生曾在诺瓦瓦克斯医药公司担任董事长达24年,该公司是一家在纳斯达克上市(简称NVAX)的临床阶段疫苗生物技术公司(Covid-19 Vaccine),在疫情期间市值超过150亿美元,他曾担任该公司的董事长、首席执行官和首席董事。埃文斯先生被安永会计师事务所评为2004年西南地区能源行业年度企业家,并随后入选安永企业家世界Hall of Fame。埃文斯还在2013年被评为年度能源行业领袖,并在2013年被《财经月刊》评选为最受尊敬的首席执行官之一。2013年,埃文斯先生被德州顶级制作人评选为“大公司”类最佳CEO。此外,他还获得了《财经月刊》2013年的“年度交易撮合者奖”。埃文斯是南卫理公会大学马奎尔能源研究所的董事,现在他在大麻产业会议、无线电网络和播客上就大麻产业的时事发表演讲。


Gary C. Evans,joined the Board in November 2022. He has extensive experience in the public and private financial business sectors as well as entrepreneurial expertise in start-up enterprises to multi-billion dollar corporations. Additionally, Gary C. Evans has a history of successful dealings with investor relations and financial institutions. This set of attributes makes Mr. Evans a great and much needed addition to United States Antimony Corporation Board. Gary C. Evans presently serves as Chairman of the Board and Chief Executive Officer of Evergreen Sustainable Enterprises, Inc. ("EGSE"), a publicly held, sustainable energy transition and hemp company that currently trades on the OTCQB with an approximate $50 Million market capitalization, a position he has held since 2016. EGSE has diversified through various acquisitions in the hemp industry, predominantly within the midstream sector. Mr. Evans previously led Magnum Hunter Resources Corporation, a NYSE listed multibillion-dollar public energy company specializing in unconventional resource plays predominately in the Appalachian Basin and the Eagle Ford, from 2009 to 2016. These corporate assets are now part of Southwestern Energy Co. (NYSE: SWN). Mr. Evans was also founder and CEO of Eureka Hunter Holdings, LLC, a mid-stream gas gathering company transporting and managing up to 1 BCF of daily natural gas volumes from wells producing in West Virginia and Ohio on approximately 200 miles of newly constructed pipeline during the similar seven-year period. Additionally, Mr. Evans previously founded and served as the Chairman and Chief Executive Officer of Magnum Hunter Resources Inc. (MHRI), a NYSE listed company, for twenty years before selling MHRI to Cimarex Energy for approximately $2.2 billion in June 2005. These assets are now part of Coterra Energy, Inc. (NYSE: CTRA). Throughout his career, Mr. Evans has raised various forms of capital on Wall Street that have exceeded $7 Billion. Mr. Evans has previously served for 24 years as a Director of Novavax Inc., a NASDAQ listed ("NVAX") clinical-stage vaccine biotechnology company (Covid-19 Vaccine) which reached a market capitalization in excess of $15 Billion during the pandemic, where he previously also served as Chairman, CEO and Lead Director. Mr. Evans was recognized by Ernst and Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy Sector and was subsequently inducted into the World Hall of Fame for Ernst & Young Entrepreneurs. Mr. Evans was also recognized as the Energy Industry Leader of the year in 2013 and chosen by Finance Monthly in 2013 as one of the most respected CEO's. Mr. Evans was chosen as the Best CEO in the "Large Company" category by Texas Top Producers in 2013. He additionally won the Deal Maker of the Year Award in 2013 by Finance Monthly. Mr. Evans serves on the Board of the Maguire Energy Institute at Southern Methodist University and now speaks on the current affairs of the hemp industry at hemp industry conferences, on radio networks, and podcasts.
Gary C. Evans于2022年11月加入董事会。他在公共和私营金融业务部门拥有丰富的经验,并在数十亿美元公司的初创企业中拥有创业专长。此外,Gary C. Evans也有与投资者关系和金融机构成功打交道的历史。这一系列的特点使埃文斯先生成为一个伟大的和非常需要的补充United States Antimony Corporation董事会。Gary C. Evans目前担任Evergreen Sustainable Enterprises,Inc.(EGSE)董事会主席兼首席执行官,该公司是一家上市的可持续能源转型和大麻公司,目前在OTCQB交易,市值约为5000万美元,自2016年以来一直担任该职位。EGSE通过在大麻行业的各种收购实现了多元化,主要是在中游行业。埃文斯曾于2009年至2016年领导Magnum Hunter Resources Corporation,这是一家在纽约证券交易所上市、市值数十亿美元的公共能源公司,专门从事主要在阿巴拉契亚盆地和鹰福特的非常规资源开发。这些公司资产现在是西南能源公司(纽约证券交易所代码:SWN)的一部分。埃文斯还是Eureka Hunter Holdings,LLC的创始人和首席执行官,该公司是一家中游天然气采集公司,在类似的七年期间,从西弗吉尼亚州和俄亥俄州新建的约200英里管道上的油井生产天然气,每天输送和管理的天然气量高达1 BCF。此外,埃文斯先生曾在纽约证券交易所上市公司Magnum Hunter能源公司(Magnum Hunter Resources Inc.,简称MHRI)创立并担任董事长兼首席执行官长达20年,然后于2005年6月以大约22亿美元的价格将MHRI出售给Cimarex能源。这些资产现在是Coterra Energy公司(纽约证券交易所代码:CTRA)的一部分。在整个职业生涯中,埃文斯在华尔街筹集了超过70亿美元的各种形式的资金。埃文斯先生曾在诺瓦瓦克斯医药公司担任董事长达24年,该公司是一家在纳斯达克上市(简称NVAX)的临床阶段疫苗生物技术公司(Covid-19 Vaccine),在疫情期间市值超过150亿美元,他曾担任该公司的董事长、首席执行官和首席董事。埃文斯先生被安永会计师事务所评为2004年西南地区能源行业年度企业家,并随后入选安永企业家世界Hall of Fame。埃文斯还在2013年被评为年度能源行业领袖,并在2013年被《财经月刊》评选为最受尊敬的首席执行官之一。2013年,埃文斯先生被德州顶级制作人评选为“大公司”类最佳CEO。此外,他还获得了《财经月刊》2013年的“年度交易撮合者奖”。埃文斯是南卫理公会大学马奎尔能源研究所的董事,现在他在大麻产业会议、无线电网络和播客上就大麻产业的时事发表演讲。
Gary C. Evans,joined the Board in November 2022. He has extensive experience in the public and private financial business sectors as well as entrepreneurial expertise in start-up enterprises to multi-billion dollar corporations. Additionally, Gary C. Evans has a history of successful dealings with investor relations and financial institutions. This set of attributes makes Mr. Evans a great and much needed addition to United States Antimony Corporation Board. Gary C. Evans presently serves as Chairman of the Board and Chief Executive Officer of Evergreen Sustainable Enterprises, Inc. ("EGSE"), a publicly held, sustainable energy transition and hemp company that currently trades on the OTCQB with an approximate $50 Million market capitalization, a position he has held since 2016. EGSE has diversified through various acquisitions in the hemp industry, predominantly within the midstream sector. Mr. Evans previously led Magnum Hunter Resources Corporation, a NYSE listed multibillion-dollar public energy company specializing in unconventional resource plays predominately in the Appalachian Basin and the Eagle Ford, from 2009 to 2016. These corporate assets are now part of Southwestern Energy Co. (NYSE: SWN). Mr. Evans was also founder and CEO of Eureka Hunter Holdings, LLC, a mid-stream gas gathering company transporting and managing up to 1 BCF of daily natural gas volumes from wells producing in West Virginia and Ohio on approximately 200 miles of newly constructed pipeline during the similar seven-year period. Additionally, Mr. Evans previously founded and served as the Chairman and Chief Executive Officer of Magnum Hunter Resources Inc. (MHRI), a NYSE listed company, for twenty years before selling MHRI to Cimarex Energy for approximately $2.2 billion in June 2005. These assets are now part of Coterra Energy, Inc. (NYSE: CTRA). Throughout his career, Mr. Evans has raised various forms of capital on Wall Street that have exceeded $7 Billion. Mr. Evans has previously served for 24 years as a Director of Novavax Inc., a NASDAQ listed ("NVAX") clinical-stage vaccine biotechnology company (Covid-19 Vaccine) which reached a market capitalization in excess of $15 Billion during the pandemic, where he previously also served as Chairman, CEO and Lead Director. Mr. Evans was recognized by Ernst and Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy Sector and was subsequently inducted into the World Hall of Fame for Ernst & Young Entrepreneurs. Mr. Evans was also recognized as the Energy Industry Leader of the year in 2013 and chosen by Finance Monthly in 2013 as one of the most respected CEO's. Mr. Evans was chosen as the Best CEO in the "Large Company" category by Texas Top Producers in 2013. He additionally won the Deal Maker of the Year Award in 2013 by Finance Monthly. Mr. Evans serves on the Board of the Maguire Energy Institute at Southern Methodist University and now speaks on the current affairs of the hemp industry at hemp industry conferences, on radio networks, and podcasts.
Gregg H. Alton

Gregg H. Alton,他是公司的执行副总裁,负责公司和医疗事务。他于1999年加入公司,担任法律总顾问(从2000年到2009年当选现任职务)。担任现任职务期间,他负责法律事务、政务、医疗事务、公共事务和新兴市场活动。加入Gilead 公司之前,他曾担任Cooley Godward 公司的律师事务所的律师,在那里他专注于医疗保健和信息技术公司的并购、企业合作和企业融资交易。他是the AIDSInstitute 、Bay Bio(旧金山海湾地区生命科学行业组织)、Oaklandand Celladon Corporation(男孩女孩俱乐部)的董事会成员。他也是the U.S.Government ’sIndustry Trade Advisory Committeeon Intellectual Property Rights 、UCSFGlobal Health Sciences 的顾问委员会、Stanford Law School 的院长的顾问委员会成员。他持有加州大学伯克利分校(the University of Californiaat Berkeley)的法律研究学士学位,以及斯坦福大学(Stanford University)的法学博士学位。于2021年7月13日获委任为腾盛博药生物科技有限公司独立非执行董事。


Gregg H. Alton is responsible for the company's strategy, growth and operations. As Chief Patient Officer, he leads Gilead's patient outreach and engagement initiatives and the company's efforts to facilitate access to its medicines around the world. He oversees Gilead's corporate and medical affairs functions and developing world access programs, as well as its digital patient solutions and patient-centered outcomes groups and commercial operations in certain countries. Since joining Gilead in 1999 Mr. Alton has held a number of positions at the company with experience in legal, medical affairs, policy and commercial. He previously served as Interim Chief Executive Officer and General Counsel.
Gregg H. Alton,他是公司的执行副总裁,负责公司和医疗事务。他于1999年加入公司,担任法律总顾问(从2000年到2009年当选现任职务)。担任现任职务期间,他负责法律事务、政务、医疗事务、公共事务和新兴市场活动。加入Gilead 公司之前,他曾担任Cooley Godward 公司的律师事务所的律师,在那里他专注于医疗保健和信息技术公司的并购、企业合作和企业融资交易。他是the AIDSInstitute 、Bay Bio(旧金山海湾地区生命科学行业组织)、Oaklandand Celladon Corporation(男孩女孩俱乐部)的董事会成员。他也是the U.S.Government ’sIndustry Trade Advisory Committeeon Intellectual Property Rights 、UCSFGlobal Health Sciences 的顾问委员会、Stanford Law School 的院长的顾问委员会成员。他持有加州大学伯克利分校(the University of Californiaat Berkeley)的法律研究学士学位,以及斯坦福大学(Stanford University)的法学博士学位。于2021年7月13日获委任为腾盛博药生物科技有限公司独立非执行董事。
Gregg H. Alton is responsible for the company's strategy, growth and operations. As Chief Patient Officer, he leads Gilead's patient outreach and engagement initiatives and the company's efforts to facilitate access to its medicines around the world. He oversees Gilead's corporate and medical affairs functions and developing world access programs, as well as its digital patient solutions and patient-centered outcomes groups and commercial operations in certain countries. Since joining Gilead in 1999 Mr. Alton has held a number of positions at the company with experience in legal, medical affairs, policy and commercial. He previously served as Interim Chief Executive Officer and General Counsel.
Stanley C. Erck

Stanley C. Erck, 从2011年4月起,他担任Novavax, Inc.的首席执行官。从2010年2月至2011年4月,他担任Novavax, Inc.的执行主席和董事,从2009年6月起,担任董事。从2000年至2008年,他担任疫苗开发公司Iomai Corporation的总裁、首席执行官和董事,该公司于2008年被Intercell收购。在此之前,他曾担任上市免疫公司Procept、Integrated Genetics(现在是Genzyme Corporation)、Baxter International的领导层职位。他目前是BioCryst Pharmaceuticals、MaxCyte, Inc.、和MdBio Foundation的董事会成员。


Stanley C. Erck,Novavax, Inc.,President and Chief Executive Officer of Novavax, Inc. April 2011 to present.Interim Chief Financial Officer (November 2017 to March 2018).Executive Chairman (February 2010 to April 2011).Iomai Corporation President and Chief Executive Officer (2000 to 2008 when it was acquired by Intercell AG).Mr. Erck previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International.M.B.A., University of Chicago.Bachelor of Science in Economics, University of Illinois.
Stanley C. Erck, 从2011年4月起,他担任Novavax, Inc.的首席执行官。从2010年2月至2011年4月,他担任Novavax, Inc.的执行主席和董事,从2009年6月起,担任董事。从2000年至2008年,他担任疫苗开发公司Iomai Corporation的总裁、首席执行官和董事,该公司于2008年被Intercell收购。在此之前,他曾担任上市免疫公司Procept、Integrated Genetics(现在是Genzyme Corporation)、Baxter International的领导层职位。他目前是BioCryst Pharmaceuticals、MaxCyte, Inc.、和MdBio Foundation的董事会成员。
Stanley C. Erck,Novavax, Inc.,President and Chief Executive Officer of Novavax, Inc. April 2011 to present.Interim Chief Financial Officer (November 2017 to March 2018).Executive Chairman (February 2010 to April 2011).Iomai Corporation President and Chief Executive Officer (2000 to 2008 when it was acquired by Intercell AG).Mr. Erck previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International.M.B.A., University of Chicago.Bachelor of Science in Economics, University of Illinois.
James F. Young

James F. Young, 他是MedImmune, Inc.的前研发总裁。从2010年4月起,他担任Novavax, Inc.的董事并从2011年4月起,担任董事会主席。从2000年至2008年,他担任MedImmune, Inc.的研发总裁;从1999年至2000年,担任研发执行副总裁;从1995年至1999年,担任高级副总裁;并从1989年至1995年,担任研发高级副总裁。他目前是开发新抗病毒药物治疗的私人生物制药公司3-V Biosciences, Inc.的董事会成员;并是开发清洁煤炭技术公司MicroCoal Technologies Inc.的董事会主席。


James F. Young,Targeted Microwave Solutions, Inc.,Former Chairman of the Board and Chief Executive Officer 2016 to 2018.MedImmune, Inc.,Former President, Research and Development (2000 to 2008).Executive Vice President, Research and Development (1999 to 2000).Senior Vice President (1995 to 1999).Senior Vice President, Research and Development (1989 to 1995).Ph.D. in Microbiology and Immunology, Baylor College of Medicine.Bachelor of Science degrees in General Science and Biology, Villanova University.
James F. Young, 他是MedImmune, Inc.的前研发总裁。从2010年4月起,他担任Novavax, Inc.的董事并从2011年4月起,担任董事会主席。从2000年至2008年,他担任MedImmune, Inc.的研发总裁;从1999年至2000年,担任研发执行副总裁;从1995年至1999年,担任高级副总裁;并从1989年至1995年,担任研发高级副总裁。他目前是开发新抗病毒药物治疗的私人生物制药公司3-V Biosciences, Inc.的董事会成员;并是开发清洁煤炭技术公司MicroCoal Technologies Inc.的董事会主席。
James F. Young,Targeted Microwave Solutions, Inc.,Former Chairman of the Board and Chief Executive Officer 2016 to 2018.MedImmune, Inc.,Former President, Research and Development (2000 to 2008).Executive Vice President, Research and Development (1999 to 2000).Senior Vice President (1995 to 1999).Senior Vice President, Research and Development (1989 to 1995).Ph.D. in Microbiology and Immunology, Baylor College of Medicine.Bachelor of Science degrees in General Science and Biology, Villanova University.
Rajiv I. Modi

Rajiv I. Modi, 从1995年起,他担任印度公司Cadila Pharmaceuticals, Ltd. “Cadila”的总经理。当时由于与该公司最大股东之间的关系,他被选进董事会。2014年4月16日,Cadila的一家子公司Satellite Overseas (Holdings) Limited 拥有公司大约4.5%的有效普通股。他目前是Cadila集团公司的董事会成员。


Rajiv I. Modi,Cadila Pharmaceuticals, Ltd.,Chairman and Managing Director 1995 to present.Ph.D. in Biological Science, University of Michigan.Bachelor’s degree of Technology in Chemical Engineering, University College, London.
Rajiv I. Modi, 从1995年起,他担任印度公司Cadila Pharmaceuticals, Ltd. “Cadila”的总经理。当时由于与该公司最大股东之间的关系,他被选进董事会。2014年4月16日,Cadila的一家子公司Satellite Overseas (Holdings) Limited 拥有公司大约4.5%的有效普通股。他目前是Cadila集团公司的董事会成员。
Rajiv I. Modi,Cadila Pharmaceuticals, Ltd.,Chairman and Managing Director 1995 to present.Ph.D. in Biological Science, University of Michigan.Bachelor’s degree of Technology in Chemical Engineering, University College, London.
Michael A. McManus, Jr.

Michael A. McManus, Jr., 2006年起,他担任A. Schulman的董事,目前是审计委员会和提名与公司管理委员会成员。1999年起,他担任医疗设备制造商Misonix, Inc.的总裁和首席执行官。在此之前,他在New York Bancorp, Inc., Jamcor Pharmaceutical, Inc., Pfizer, Inc.和Revlon Corp.担任执行官职位。他目前担任Novavax, Inc.和Misonix, Inc.的董事,在过去5年内,担任American Home Mortgage Investment Corp.的董事。提名与公司管理委员会任务他作为首席执行官、上市公司董事和A. Schulman的董事经历积累的经验、技能和资质使他能够为董事会提供持久的商业和公司管理专业知识,所以提名他再次竞选。


Michael A. McManus, Jr.,Misonix, Inc.,President and Chief Executive Officer 1999 to 2016.New York Bancorp Inc.,President, Chief Executive Officer and Director (1991 to March 1998). President and Chief Executive Officer, Home Federal Savings Bank, the principal subsidiary of New York Bancorp Inc. (February 1995 to March 1998).Jamcor Pharmaceuticals Inc.,President and Chief Executive Officer (1990 to November 1991).Office of the President of the United States,Assistant to the President of the United States (1982 to 1985).Mr. McManus held previous positions at Pfizer Inc. and Revlon Group.
Michael A. McManus, Jr., 2006年起,他担任A. Schulman的董事,目前是审计委员会和提名与公司管理委员会成员。1999年起,他担任医疗设备制造商Misonix, Inc.的总裁和首席执行官。在此之前,他在New York Bancorp, Inc., Jamcor Pharmaceutical, Inc., Pfizer, Inc.和Revlon Corp.担任执行官职位。他目前担任Novavax, Inc.和Misonix, Inc.的董事,在过去5年内,担任American Home Mortgage Investment Corp.的董事。提名与公司管理委员会任务他作为首席执行官、上市公司董事和A. Schulman的董事经历积累的经验、技能和资质使他能够为董事会提供持久的商业和公司管理专业知识,所以提名他再次竞选。
Michael A. McManus, Jr.,Misonix, Inc.,President and Chief Executive Officer 1999 to 2016.New York Bancorp Inc.,President, Chief Executive Officer and Director (1991 to March 1998). President and Chief Executive Officer, Home Federal Savings Bank, the principal subsidiary of New York Bancorp Inc. (February 1995 to March 1998).Jamcor Pharmaceuticals Inc.,President and Chief Executive Officer (1990 to November 1991).Office of the President of the United States,Assistant to the President of the United States (1982 to 1985).Mr. McManus held previous positions at Pfizer Inc. and Revlon Group.
Margaret G. McGlynn

Margaret G. McGlynn, 自2011年7月以来,她一直担任国际艾滋病疫苗倡议的总裁兼首席执行官,该组织是一个全球非营利组织,其宗旨是确保HIV疫苗在整个世界能被安全,有效,方便得开发利用。她自从2005年到2009年一直致力于疫苗和传染病研究的美国默克制药公司。她于1983年加入默克制药公司,在各种市场营销,销售和服务管理式医疗扮演多个角色。目前,她是空气产品和化学品公司董事会的一员,该公司专门从事工业实用的气体和化学品。她同样也是一家生物制药公司— Amicus Therapeutics公司董事会的一员。她是全国工业咨询委员会在大学药学和制药科学布法罗学院的一员。麦格林女士持有药学学士学位和市场营销学硕士学位,并获纽约州立大学水牛城分校荣誉博士学位。


Margaret G. McGlynn Retired from Merck & Co. in 2009 where she served as President, Vaccines and Infectious Diseases and as President, Hospital and Specialty Products.Held various leadership roles in the U.S. and globally in marketing, sales, managed care, and business development during her 26-year career at Merck.President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015.Member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.Member of the Board of Directors of Air Products and Chemicals, Inc., a publicly traded company specializing in gases and chemicals for industrial uses, from 2005 to November 2020.Holds a B.S. in Pharmacy, an M.B.A. in Marketing, and an Honorary Doctorate from the State University of New York at Buffalo.
Margaret G. McGlynn, 自2011年7月以来,她一直担任国际艾滋病疫苗倡议的总裁兼首席执行官,该组织是一个全球非营利组织,其宗旨是确保HIV疫苗在整个世界能被安全,有效,方便得开发利用。她自从2005年到2009年一直致力于疫苗和传染病研究的美国默克制药公司。她于1983年加入默克制药公司,在各种市场营销,销售和服务管理式医疗扮演多个角色。目前,她是空气产品和化学品公司董事会的一员,该公司专门从事工业实用的气体和化学品。她同样也是一家生物制药公司— Amicus Therapeutics公司董事会的一员。她是全国工业咨询委员会在大学药学和制药科学布法罗学院的一员。麦格林女士持有药学学士学位和市场营销学硕士学位,并获纽约州立大学水牛城分校荣誉博士学位。
Margaret G. McGlynn Retired from Merck & Co. in 2009 where she served as President, Vaccines and Infectious Diseases and as President, Hospital and Specialty Products.Held various leadership roles in the U.S. and globally in marketing, sales, managed care, and business development during her 26-year career at Merck.President and Chief Executive Officer of the International AIDS Vaccine Initiative, a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 until 2015.Member of the National Industrial Advisory Committee at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.Member of the Board of Directors of Air Products and Chemicals, Inc., a publicly traded company specializing in gases and chemicals for industrial uses, from 2005 to November 2020.Holds a B.S. in Pharmacy, an M.B.A. in Marketing, and an Honorary Doctorate from the State University of New York at Buffalo.
Gary C. Evans

Gary C. Evans, 他一直担任Magnum Hunter公司的董事(2009年以来)。他于2009年5月被任命为公司的董事会主席和首席执行官。他曾创立Magnum Hunter Resources公司(纽交所上市的公司)并任职20年,担任主席和首席执行官。他于2005年6月以大约22亿美元将MHRI公司出售给Cimarex Energy公司。他于2005年创立了Wind Energy公司(可再生能源公司,于2006年12月被GreenHunter Resources公司收购)。GreenHunter Resources公司在纽约证交所上市,专注于非常规资源的油田水管理和清洁水技术。他曾担任GreenHunter公司的主席(2006年12月以来),以及GreenHunter 公司的临时首席执行官(2014年1月15日以来)。此前,他曾担任GreenHunter 公司的首席执行官(从2006年12月到2012年12月)。他目前担任TEL Offshore Trust公司(上市的石油和天然气的信托公司)的个人受托人,以及Novavax 公司(在纳斯达克上市的临床阶段疫苗生物科技公司)的董事。他曾荣获安永会计师事务所(Ernst & Young)西南地区的能源部门2004年年度企业家,随后被纳入安永企业家世界名人堂。他也在2013年荣获能源行业的领袖称号,并于2013年由《金融月刊》(Finance Monthly) 授予最受人尊敬的首席执行官的荣誉称号。他于2013年被德克萨斯州的顶级生产商选为德州“大公司”的最佳首席执行官。他另外于2013年赢得《金融月刊》(Finance Monthly)颁发的交易撮合人奖。他任职于南卫理公会大学马奎尔能源研究所( the Maguire Energy Institute at Southern Methodist University)的董事会,并经常在能源行业会议就世界各地的时事石油和天然气业务发表演说。


Gary C. Evans, Chairman of the Board and Chief Executive Officer. Mr. Evans previously led Magnum Hunter Resources Corporation, a public energy company specializing in unconventional resource plays predominately in the Appalachian Basin, for seven years, from 2009 to May 2016. Mr. Evans was also founder and CEO of Eureka Hunter Holdings, LLC, a mid-stream gas gathering company transporting and managing up to 1 Bcf of daily natural gas volumes from production in West Virginia and Ohio on approximately 200 miles of newly constructed pipeline during the similar seven-year period. Additionally, Mr. Evans previously founded and served as the Chairman and Chief Executive Officer of Magnum Hunter Resources Inc. MHRI, a NYSE listed company, for 20 years before MHRI was acquired by Cimarex Energy for approximately $2.2 billion in June 2005. Later that year, Mr. Evans formed Wind Hunter Energy, LLC, a renewable energy company which was subsequently acquired in December 2006 by GreenHunter Energy, Inc., an emerging water resource company focusing on oil field water management and clean water technologies active in the Marcellus and Utica resource plays in Appalachia. As founder, Mr. Evans served as Chairman and Chief Executive Officer of GreenHunter Energy, Inc. from December 2006 until May 2016. Its assets were sold to a private equity fund. Mr. Evans serves as an Individual Trustee of TEL Offshore Trust, a publicly listed oil and gas trust, and is a Director of Novavax Inc., a NASDAQ listed clinical-stage vaccine biotechnology company, where he previously served as Chairman, CEO and Lead Director. Mr. Evans was recognized by Ernst & Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy Sector and was subsequently inducted into the World Hall of Fame for Ernst & Young Entrepreneurs. Mr. Evans was also recognized as the Energy Industry Leader of the year in 2013 and chosen by Finance Monthly in 2013 as one of the most respected CEOs. Mr. Evans was chosen as the Best CEO in the “Large Company” category by Texas Top Producers in 2013. He additionally won the Deal Maker of the Year Award in 2013 by Finance Monthly. Mr. Evans serves on the board of the Maguire Energy Institute at Southern Methodist University and speaks regularly at energy industry conferences around the world and on national television networks on the current affairs of the oil and gas industry.
Gary C. Evans, 他一直担任Magnum Hunter公司的董事(2009年以来)。他于2009年5月被任命为公司的董事会主席和首席执行官。他曾创立Magnum Hunter Resources公司(纽交所上市的公司)并任职20年,担任主席和首席执行官。他于2005年6月以大约22亿美元将MHRI公司出售给Cimarex Energy公司。他于2005年创立了Wind Energy公司(可再生能源公司,于2006年12月被GreenHunter Resources公司收购)。GreenHunter Resources公司在纽约证交所上市,专注于非常规资源的油田水管理和清洁水技术。他曾担任GreenHunter公司的主席(2006年12月以来),以及GreenHunter 公司的临时首席执行官(2014年1月15日以来)。此前,他曾担任GreenHunter 公司的首席执行官(从2006年12月到2012年12月)。他目前担任TEL Offshore Trust公司(上市的石油和天然气的信托公司)的个人受托人,以及Novavax 公司(在纳斯达克上市的临床阶段疫苗生物科技公司)的董事。他曾荣获安永会计师事务所(Ernst & Young)西南地区的能源部门2004年年度企业家,随后被纳入安永企业家世界名人堂。他也在2013年荣获能源行业的领袖称号,并于2013年由《金融月刊》(Finance Monthly) 授予最受人尊敬的首席执行官的荣誉称号。他于2013年被德克萨斯州的顶级生产商选为德州“大公司”的最佳首席执行官。他另外于2013年赢得《金融月刊》(Finance Monthly)颁发的交易撮合人奖。他任职于南卫理公会大学马奎尔能源研究所( the Maguire Energy Institute at Southern Methodist University)的董事会,并经常在能源行业会议就世界各地的时事石油和天然气业务发表演说。
Gary C. Evans, Chairman of the Board and Chief Executive Officer. Mr. Evans previously led Magnum Hunter Resources Corporation, a public energy company specializing in unconventional resource plays predominately in the Appalachian Basin, for seven years, from 2009 to May 2016. Mr. Evans was also founder and CEO of Eureka Hunter Holdings, LLC, a mid-stream gas gathering company transporting and managing up to 1 Bcf of daily natural gas volumes from production in West Virginia and Ohio on approximately 200 miles of newly constructed pipeline during the similar seven-year period. Additionally, Mr. Evans previously founded and served as the Chairman and Chief Executive Officer of Magnum Hunter Resources Inc. MHRI, a NYSE listed company, for 20 years before MHRI was acquired by Cimarex Energy for approximately $2.2 billion in June 2005. Later that year, Mr. Evans formed Wind Hunter Energy, LLC, a renewable energy company which was subsequently acquired in December 2006 by GreenHunter Energy, Inc., an emerging water resource company focusing on oil field water management and clean water technologies active in the Marcellus and Utica resource plays in Appalachia. As founder, Mr. Evans served as Chairman and Chief Executive Officer of GreenHunter Energy, Inc. from December 2006 until May 2016. Its assets were sold to a private equity fund. Mr. Evans serves as an Individual Trustee of TEL Offshore Trust, a publicly listed oil and gas trust, and is a Director of Novavax Inc., a NASDAQ listed clinical-stage vaccine biotechnology company, where he previously served as Chairman, CEO and Lead Director. Mr. Evans was recognized by Ernst & Young as the Southwest Area 2004 Entrepreneur of the Year for the Energy Sector and was subsequently inducted into the World Hall of Fame for Ernst & Young Entrepreneurs. Mr. Evans was also recognized as the Energy Industry Leader of the year in 2013 and chosen by Finance Monthly in 2013 as one of the most respected CEOs. Mr. Evans was chosen as the Best CEO in the “Large Company” category by Texas Top Producers in 2013. He additionally won the Deal Maker of the Year Award in 2013 by Finance Monthly. Mr. Evans serves on the board of the Maguire Energy Institute at Southern Methodist University and speaks regularly at energy industry conferences around the world and on national television networks on the current affairs of the oil and gas industry.
Richard H. Douglas

Richard H. Douglas, 他是Genzyme Corporation的前公司发展高级副总裁。从1989年至2011年,他领导Genzyme Corporation的公司发展团队,并参与多个收购、授权、融资、合资和战略联盟。从1982年起至1989年与Genzyme Corporation合并,他在Integrated Genetics科学与公司发展部门工作。他曾在加州理工学院(California Institute of Technology)勒罗伊胡德实验室担任博士后研究员。他是密歇根大学(University of Michigan)技术转让国家咨询委员会成员。他在加利福尼亚大学(University of California)伯克利分校获得生物化学博士学位,并在密歇根大学(University of Michigan)获得化学学士学位。


Richard H. Douglas,has served on Aldeyra Therapeutics, Inc. Board since September 2016. Dr. Douglas was formerly Senior Vice President, Corporate Development of Genzyme Corporation. From 1989 to 2011, he led Genzyme Corporation's Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the board of directors of Novavax, Inc., a publicly-traded clinical-stage vaccine company; MaxCyte, Inc., a publicly traded instrument and immunotherapeutic company; and the University of Michigan Technology Transfer National Advisory Board. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in Leroy Hood's laboratory at the California Institute of Technology.
Richard H. Douglas, 他是Genzyme Corporation的前公司发展高级副总裁。从1989年至2011年,他领导Genzyme Corporation的公司发展团队,并参与多个收购、授权、融资、合资和战略联盟。从1982年起至1989年与Genzyme Corporation合并,他在Integrated Genetics科学与公司发展部门工作。他曾在加州理工学院(California Institute of Technology)勒罗伊胡德实验室担任博士后研究员。他是密歇根大学(University of Michigan)技术转让国家咨询委员会成员。他在加利福尼亚大学(University of California)伯克利分校获得生物化学博士学位,并在密歇根大学(University of Michigan)获得化学学士学位。
Richard H. Douglas,has served on Aldeyra Therapeutics, Inc. Board since September 2016. Dr. Douglas was formerly Senior Vice President, Corporate Development of Genzyme Corporation. From 1989 to 2011, he led Genzyme Corporation's Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the board of directors of Novavax, Inc., a publicly-traded clinical-stage vaccine company; MaxCyte, Inc., a publicly traded instrument and immunotherapeutic company; and the University of Michigan Technology Transfer National Advisory Board. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in Leroy Hood's laboratory at the California Institute of Technology.
David M. Mott

David M. Mott自2009年12月起担任董事,自2016年4月起担任董事会主席。自2008年9月,他领导医疗保健投资实践,Mott先生曾担任New Enterprise Associates的普通合伙人,这是一家投资公司,专注于风险投资和成长股权投资。从1992年至2008年Mott先生曾在MedImmune有限公司工作,这是一家生物技术公司也是AstraZeneca Plc公司,该公司在纽约证券交易所代码为AZN(NYSE:AZN)的子公司,从2000年10月至2008年7月他在任期内担任多种职务,包括财务总监,总裁兼首席运营官,最近担任首席执行官,在此期间,Mott先生从2007年6月至2008年7月在AstraZeneca Plc公司任职执行副总裁,该公司于2007年6月被MedImmune有限公司收购。加盟MedImmune有限公司之前,Mott先生在Smith Barney, Harris Upham公司担任医疗保健银行投资副总裁职位。Mott先生获得了达特茅斯学院(Dartmouth College)文学士学位。Mott先生还担任Prosensa控股公司,该公司全国证券交易商自动报价系统协会代码为RNA(NASDAQ:RNA)的董事长,并担任Epizyme公司,该公司全国证券交易商自动报价系统协会代码为EPZM(NASDAQ:EPZM)的董事会成员,还担任多个私人持有的生命科学公司董事会成员。


David M. Mott,MedImmune,President and Chief Executive Officer, Vice Chairman 2000 to 2008 during which he led the sale of the company to AstraZeneca in June 2007 for $15.6 billion.Served in various senior roles, including Chief Operating Officer and Chief Financial Officer (1992 to 2000).During the course of his career, Mr. Mott has been involved in more than $40 billion in corporate acquisitions, fundraising, partnerships and other capital formation ventures. He has supported more than 35 initial public offerings or corporate acquisitions, overseen more than a dozen new drugs from development to commercialization, and served on 25 corporate boards.Bachelor of Arts, Dartmouth College.
David M. Mott自2009年12月起担任董事,自2016年4月起担任董事会主席。自2008年9月,他领导医疗保健投资实践,Mott先生曾担任New Enterprise Associates的普通合伙人,这是一家投资公司,专注于风险投资和成长股权投资。从1992年至2008年Mott先生曾在MedImmune有限公司工作,这是一家生物技术公司也是AstraZeneca Plc公司,该公司在纽约证券交易所代码为AZN(NYSE:AZN)的子公司,从2000年10月至2008年7月他在任期内担任多种职务,包括财务总监,总裁兼首席运营官,最近担任首席执行官,在此期间,Mott先生从2007年6月至2008年7月在AstraZeneca Plc公司任职执行副总裁,该公司于2007年6月被MedImmune有限公司收购。加盟MedImmune有限公司之前,Mott先生在Smith Barney, Harris Upham公司担任医疗保健银行投资副总裁职位。Mott先生获得了达特茅斯学院(Dartmouth College)文学士学位。Mott先生还担任Prosensa控股公司,该公司全国证券交易商自动报价系统协会代码为RNA(NASDAQ:RNA)的董事长,并担任Epizyme公司,该公司全国证券交易商自动报价系统协会代码为EPZM(NASDAQ:EPZM)的董事会成员,还担任多个私人持有的生命科学公司董事会成员。
David M. Mott,MedImmune,President and Chief Executive Officer, Vice Chairman 2000 to 2008 during which he led the sale of the company to AstraZeneca in June 2007 for $15.6 billion.Served in various senior roles, including Chief Operating Officer and Chief Financial Officer (1992 to 2000).During the course of his career, Mr. Mott has been involved in more than $40 billion in corporate acquisitions, fundraising, partnerships and other capital formation ventures. He has supported more than 35 initial public offerings or corporate acquisitions, overseen more than a dozen new drugs from development to commercialization, and served on 25 corporate boards.Bachelor of Arts, Dartmouth College.
Rachel K. King

Rachel K. King,她是我们公司的联合创始人,自2003年我们公司成立起,她一直担任我们的总裁和首席执行官以及董事。之前,自2001年至2003年,她曾担任 New Enterprise Associates(一个风险资本公司)的常驻总经理。自1999年至2001年,她担任Novartis Corporation(一个制药公司)的高级副总裁。在加入Novartis 之前,她在 Genetic Therapy, Inc.(一个生物技术公司)任职10年,在该公司,作为执行团队的一员,她担任过许多职务。在被Novartis收购后,她担任 Genetic Therapy(Novartis的全资子公司)的首席执行官。她曾任职于 Alza Corporation(一个制药和医疗系统公司,后被Johnson & Johnson收购)和Bain and Company(一个管理咨询公司)。她取得了 Dartmouth College的学士学位,以及Harvard Business School工商管理学硕士学位。目前,她担任the Biotechnology Industry Organization的董事长并被马里兰政府任命为Maryland Life Sciences Advisory Board的主席。


Rachel K. King is a co-founder of our company and has served as our President and Chief Executive Officer and as a member of our Board since our inception in 2003. Previously, Ms. King was an Executive in Residence at NEA from 2001 to 2003. From 1999 to 2001 Ms. King served as a Senior Vice President of Novartis Corporation, a pharmaceutical company. Before joining Novartis, Ms. King spent 10 years with Genetic Therapy, Inc., a biotechnology company, where she served in a number of roles as part of the executive team, which included the company’s initial public offering and later acquisition by Novartis. After the acquisition by Novartis, she served as Chief Executive Officer of Genetic Therapy, which was then a wholly owned subsidiary of Novartis. Ms. King previously worked at Alza Corporation, a pharmaceutical and medical systems company that was later acquired by Johnson & Johnson, as well as at Bain and Company, a management consulting firm. Since July 2016 Ms. King serves on the board of directors of Warp Drive Bio, a privately held life sciences company developing therapeutics that exploit the molecules and mechanisms of nature. She received a B.A. from Dartmouth College and an M.B.A. from Harvard Business School. Ms. King was appointed by Maryland’s governor as Chair of the Maryland Life Sciences Advisory Board and served as Chair of the Board of the Biotechnology Industry Organization from 2013 to 2015.
Rachel K. King,她是我们公司的联合创始人,自2003年我们公司成立起,她一直担任我们的总裁和首席执行官以及董事。之前,自2001年至2003年,她曾担任 New Enterprise Associates(一个风险资本公司)的常驻总经理。自1999年至2001年,她担任Novartis Corporation(一个制药公司)的高级副总裁。在加入Novartis 之前,她在 Genetic Therapy, Inc.(一个生物技术公司)任职10年,在该公司,作为执行团队的一员,她担任过许多职务。在被Novartis收购后,她担任 Genetic Therapy(Novartis的全资子公司)的首席执行官。她曾任职于 Alza Corporation(一个制药和医疗系统公司,后被Johnson & Johnson收购)和Bain and Company(一个管理咨询公司)。她取得了 Dartmouth College的学士学位,以及Harvard Business School工商管理学硕士学位。目前,她担任the Biotechnology Industry Organization的董事长并被马里兰政府任命为Maryland Life Sciences Advisory Board的主席。
Rachel K. King is a co-founder of our company and has served as our President and Chief Executive Officer and as a member of our Board since our inception in 2003. Previously, Ms. King was an Executive in Residence at NEA from 2001 to 2003. From 1999 to 2001 Ms. King served as a Senior Vice President of Novartis Corporation, a pharmaceutical company. Before joining Novartis, Ms. King spent 10 years with Genetic Therapy, Inc., a biotechnology company, where she served in a number of roles as part of the executive team, which included the company’s initial public offering and later acquisition by Novartis. After the acquisition by Novartis, she served as Chief Executive Officer of Genetic Therapy, which was then a wholly owned subsidiary of Novartis. Ms. King previously worked at Alza Corporation, a pharmaceutical and medical systems company that was later acquired by Johnson & Johnson, as well as at Bain and Company, a management consulting firm. Since July 2016 Ms. King serves on the board of directors of Warp Drive Bio, a privately held life sciences company developing therapeutics that exploit the molecules and mechanisms of nature. She received a B.A. from Dartmouth College and an M.B.A. from Harvard Business School. Ms. King was appointed by Maryland’s governor as Chair of the Maryland Life Sciences Advisory Board and served as Chair of the Board of the Biotechnology Industry Organization from 2013 to 2015.

高管简历

中英对照 |  中文 |  英文
John A. Herrmann III

John A. Herrmann III自2014年3月起担任高级副总裁、总法律顾问和企业秘书;之前从2012年3月到2014年3月担任副总裁、总法律顾问和企业秘书;再往前,从2010年3月到2012年3月担任法律事务执行主管和企业秘书。加入公司之前, Herrmann曾担任Ore Pharmaceuticals总法律顾问以及Ore Pharmaceuticals(现名为Ore Pharmaceuticals)副总法律顾问。 Herrmann曾担任Celera Genomics高级顾问,在此之前,他曾担任Baxter Healthcare Renal分部高级公司顾问。 Herrmann持有 Brown University政治科学和历史学文学学士学位以及the University of Illinois法律博士学位。


John A. Herrmann III,Novavax, Inc.,Executive Vice President, Chief Legal Officer and Corporate Secretary June 2020 to present. Senior Vice President, General Counsel and Corporate Secretary (June 2014 to June 2020).Vice President, General Counsel and Corporate Secretary (March 2012 to June 2014).Executive Director, Legal Affairs and Corporate Secretary (April 2010 to March 2012).Ore Pharmaceuticals,General Counsel.Gene Logic.Deputy General Counsel (prior to Gene Logic becoming Ore Pharmaceuticals).Celera Genomics,Senior Counsel.Baxter Healthcare,Senior Corporate Counsel, Renal Division. J.D., University of Illinois.Bachelor of Arts. in Political Science and History, Brown University.
John A. Herrmann III自2014年3月起担任高级副总裁、总法律顾问和企业秘书;之前从2012年3月到2014年3月担任副总裁、总法律顾问和企业秘书;再往前,从2010年3月到2012年3月担任法律事务执行主管和企业秘书。加入公司之前, Herrmann曾担任Ore Pharmaceuticals总法律顾问以及Ore Pharmaceuticals(现名为Ore Pharmaceuticals)副总法律顾问。 Herrmann曾担任Celera Genomics高级顾问,在此之前,他曾担任Baxter Healthcare Renal分部高级公司顾问。 Herrmann持有 Brown University政治科学和历史学文学学士学位以及the University of Illinois法律博士学位。
John A. Herrmann III,Novavax, Inc.,Executive Vice President, Chief Legal Officer and Corporate Secretary June 2020 to present. Senior Vice President, General Counsel and Corporate Secretary (June 2014 to June 2020).Vice President, General Counsel and Corporate Secretary (March 2012 to June 2014).Executive Director, Legal Affairs and Corporate Secretary (April 2010 to March 2012).Ore Pharmaceuticals,General Counsel.Gene Logic.Deputy General Counsel (prior to Gene Logic becoming Ore Pharmaceuticals).Celera Genomics,Senior Counsel.Baxter Healthcare,Senior Corporate Counsel, Renal Division. J.D., University of Illinois.Bachelor of Arts. in Political Science and History, Brown University.
Stanley C. Erck

Stanley C. Erck, 从2011年4月起,他担任Novavax, Inc.的首席执行官。从2010年2月至2011年4月,他担任Novavax, Inc.的执行主席和董事,从2009年6月起,担任董事。从2000年至2008年,他担任疫苗开发公司Iomai Corporation的总裁、首席执行官和董事,该公司于2008年被Intercell收购。在此之前,他曾担任上市免疫公司Procept、Integrated Genetics(现在是Genzyme Corporation)、Baxter International的领导层职位。他目前是BioCryst Pharmaceuticals、MaxCyte, Inc.、和MdBio Foundation的董事会成员。


Stanley C. Erck,Novavax, Inc.,President and Chief Executive Officer of Novavax, Inc. April 2011 to present.Interim Chief Financial Officer (November 2017 to March 2018).Executive Chairman (February 2010 to April 2011).Iomai Corporation President and Chief Executive Officer (2000 to 2008 when it was acquired by Intercell AG).Mr. Erck previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International.M.B.A., University of Chicago.Bachelor of Science in Economics, University of Illinois.
Stanley C. Erck, 从2011年4月起,他担任Novavax, Inc.的首席执行官。从2010年2月至2011年4月,他担任Novavax, Inc.的执行主席和董事,从2009年6月起,担任董事。从2000年至2008年,他担任疫苗开发公司Iomai Corporation的总裁、首席执行官和董事,该公司于2008年被Intercell收购。在此之前,他曾担任上市免疫公司Procept、Integrated Genetics(现在是Genzyme Corporation)、Baxter International的领导层职位。他目前是BioCryst Pharmaceuticals、MaxCyte, Inc.、和MdBio Foundation的董事会成员。
Stanley C. Erck,Novavax, Inc.,President and Chief Executive Officer of Novavax, Inc. April 2011 to present.Interim Chief Financial Officer (November 2017 to March 2018).Executive Chairman (February 2010 to April 2011).Iomai Corporation President and Chief Executive Officer (2000 to 2008 when it was acquired by Intercell AG).Mr. Erck previously held leadership positions at Procept, a publicly traded immunology company, Integrated Genetics, now Sanofi Genzyme, and Baxter International.M.B.A., University of Chicago.Bachelor of Science in Economics, University of Illinois.
John Trizzino

从2010年4月起,John Trizzino担任Novavax业务发展高级副总裁。从2009年7月至2010年4月,他担任公司国际和政府联盟高级副总裁。在加入公司之前,从2006年至2009年,Mr. Trizzino担任MedImmune, Inc.疫苗专营权副总裁。从2004年至2006年,他担任ID Biomedical企业发展高级副总裁。从1997年至2004年,他担任the Henry Schein, Inc. 业务发展医疗事业部副总裁,和他们GIV分部的总经理。


John Trizzino has served as Senior Vice President, Commercial Operations since March 2014. He previously served as the Company’s Senior Vice President, Business Development from August 2010 to September 2011 and its Senior Vice President, International and Government Alliances from July 2009 to July 2010. Prior to joining the Company, Mr. Trizzino was the CEO of Immunovaccine from September 2011 to September 2013 VP, Vaccine Franchise at Medimmune, LLC, Senior Vice President, Business Development at ID Biomedical, and Vice President, Business Development in the Medical Group of Henry Schein, Inc. following his position as Vice President, General Manager of its GIV division. Mr. Trizzino also serves on the board of directors of The Maryland Tech Council. Mr. Trizzino received a B.S. from Long Island University, CW Post and a M.B.A. from New York University.
从2010年4月起,John Trizzino担任Novavax业务发展高级副总裁。从2009年7月至2010年4月,他担任公司国际和政府联盟高级副总裁。在加入公司之前,从2006年至2009年,Mr. Trizzino担任MedImmune, Inc.疫苗专营权副总裁。从2004年至2006年,他担任ID Biomedical企业发展高级副总裁。从1997年至2004年,他担任the Henry Schein, Inc. 业务发展医疗事业部副总裁,和他们GIV分部的总经理。
John Trizzino has served as Senior Vice President, Commercial Operations since March 2014. He previously served as the Company’s Senior Vice President, Business Development from August 2010 to September 2011 and its Senior Vice President, International and Government Alliances from July 2009 to July 2010. Prior to joining the Company, Mr. Trizzino was the CEO of Immunovaccine from September 2011 to September 2013 VP, Vaccine Franchise at Medimmune, LLC, Senior Vice President, Business Development at ID Biomedical, and Vice President, Business Development in the Medical Group of Henry Schein, Inc. following his position as Vice President, General Manager of its GIV division. Mr. Trizzino also serves on the board of directors of The Maryland Tech Council. Mr. Trizzino received a B.S. from Long Island University, CW Post and a M.B.A. from New York University.
Gregory Glenn

Gregory Glenn, 医学博士。从2011年1月起,他担任Novavax的研发高级副总裁,从2010年7月至2011年1月,担任高级副总裁和首席科技官。加入我公司前,他曾是Iomai Corporation的首席科技官和创始人,该公司于2008年被Intercell AG收购,他是约翰霍普金斯大学(Johns Hopkins University)公共卫生学院的国际卫生合作伙伴以及Walter Reed Army Institute of Research 的临床基本研究科学家。


Gregory Glenn,Novavax, Inc.,President, Research and Development March 2016 to present.Senior Vice President, Research and Development (January 2014 to March 2016).Senior Vice President, Chief Medical Officer (January 2011 to January 2014).Senior Vice President and Chief Scientific Officer (June 2010 to January 2011).Iomai Corporation, which was acquired by Intercell AG in 2008Chief Scientific and Founder.Johns Hopkins University's School of Public Health, Associate in International Health.Walter Reed Army Institute of Research,Clinical and Basic Research Scientist.Graduate of the Medical Research Fellowship, Walter Reed Army Institute of Research.M.D., Oral Roberts University School of Medicine.Bachelor of Arts in Biology and Chemistry, Whitman College.
Gregory Glenn, 医学博士。从2011年1月起,他担任Novavax的研发高级副总裁,从2010年7月至2011年1月,担任高级副总裁和首席科技官。加入我公司前,他曾是Iomai Corporation的首席科技官和创始人,该公司于2008年被Intercell AG收购,他是约翰霍普金斯大学(Johns Hopkins University)公共卫生学院的国际卫生合作伙伴以及Walter Reed Army Institute of Research 的临床基本研究科学家。
Gregory Glenn,Novavax, Inc.,President, Research and Development March 2016 to present.Senior Vice President, Research and Development (January 2014 to March 2016).Senior Vice President, Chief Medical Officer (January 2011 to January 2014).Senior Vice President and Chief Scientific Officer (June 2010 to January 2011).Iomai Corporation, which was acquired by Intercell AG in 2008Chief Scientific and Founder.Johns Hopkins University's School of Public Health, Associate in International Health.Walter Reed Army Institute of Research,Clinical and Basic Research Scientist.Graduate of the Medical Research Fellowship, Walter Reed Army Institute of Research.M.D., Oral Roberts University School of Medicine.Bachelor of Arts in Biology and Chemistry, Whitman College.